Ribomic Completes First Patient Registration for Achondroplasia Treatment Trial

TOKYO, Jul 02 (Pulse News Wire) – RIBOMIC Inc. (4591.T) announced the completion of the first patient registration for its domestic Phase III clinical trial of umedaptanib pegol, an anti-FGF2 aptamer aimed at treating achondroplasia in pediatric patients aged two to fourteen.

This milestone marks significant progress in the company's development pipeline and underscores efforts to validate the drug’s clinical value across multiple facilities in Japan. The Phase III trial seeks domestic approval and follows the regulatory filing disclosed on March 18, 2026.

Umedaptanib pegol, also known as RBM-007, is designed to inhibit FGF2 function strongly, potentially offering a fundamental treatment approach for achondroplasia. It has received orphan drug designation from the Ministry of Health, Labour and Welfare due to the rarity of the condition, which affects approximately one in every 25,000 newborns.

Currently, there is a high demand for effective new treatments for this disease.